Is the central nervous system a reservoir of HIV-1?

Current Opinion in HIV and AIDS

Volumn 9, Issue 6, 2014, Pages 552-558

  Gray, Lachlan R ^a,b   Roche, Michael ^a,b   Flynn, Jacqueline K ^a,b   Wesselingh, Steve L ^a,c   Gorry, Paul R ^a,b,d   Churchill, Melissa J ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Central nervous system; Cure; HIV 1; Latency; Reservoirs

Indexed keywords

NEUROTOXIN; TRANSCRIPTION FACTOR; VIRUS DNA;

ASTROCYTE; CENTRAL NERVOUS SYSTEM; EPIGENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; MACROPHAGE; MICROGLIA; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS ENTRY; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION; ANTIBODY SPECIFICITY; CYTOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

CENTRAL NERVOUS SYSTEM; HIV INFECTIONS; HIV-1; HUMANS; ORGAN SPECIFICITY; VIRAL LOAD; VIRUS LATENCY;

EID: 84924959254     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000108     Document Type: Review

References (59)

1. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
2. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, et al. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7:798-812.
3. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
4. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark. Ann Intern Med 2007; 146:87-95.
5. Lewin SR, Murray JM, Solomon A, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:140-147.
6. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105:16725-16730.
7. Deeks SG, Autran B, Berkhout B, et al. International ASSWGoHIVC. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
8. Le Douce V, Janossy A, Hallay H, et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother 2012; 67:1063-1074.
9. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
10. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011; 25:885-897.
11. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
12. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-2799.
13. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
14. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207:1694-1702.
15. Cannon PM, Kohn DB, Kiem HP. HIV eradication: from Berlin to Boston. Nat Biotechnol 2014; 32:315-316.
16. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
17. Luzuriaga K, Tabak B, Garber M, et al. Reduced HIV reservoirs after early treatment HIV-1 proviral reservoirs decay continously under sustained virologic control in early-treated HIV-1-infected children. J Infect Dis 2014; http://www.ncbi.nlm.nih.gov/pubmed/24850788. [Epub ahead of print]
18. Li JZ, Gandhi RT. The sooner, the better: more evidence that early antiretroviral therapy lowers viral reservoirs in HIV-infected infants. J Infect Dis 2014; http://www.ncbi.nlm.nih.gov/pubmed/24850791. [Epub ahead of print]
19. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202-1211.
20. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68:1169-1178.
21. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-593.
22. Choudhary SK, Archin NM, Cheema M, et al. Latent HIV-1 infection of resting CD4(+) T cells in the humanized Rag2(-)/(-) gammac(-)/(-) mouse. J Virol 2012; 86:114-120.
23. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-720.
24. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
25. Josefsson L, Eriksson S, Sinclair E, et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 2012; 206:28-34.
26. Orenstein JM, Bhat N, Yoder C, et al. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. AIDS 2000; 14:1709-1715.
27. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology 2012; 9:82.
28. Meltzer MS, Kornbluth RS, Hansen B, et al. HIV infection of the lung. Role of virus-infected macrophages in the pathophysiology of pulmonary disease. Chest 1993; 103:103S-108S.
29. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002; 8:522-526.
30. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998; 72:617-623.
31. Churchill MJ, Gorry PR, Cowley D, et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006; 12:146-152.
32. Thompson KA, Cherry CL, Bell JE, et al. Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol 2011; 179:1623-1629.
33. Brew BJ, Gray L, Lewin S, et al. Is specific HIV eradication from the brain possible or needed? Expert Opin Biol Ther 2013; 13:403-409.
34. Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012; 9:5-15.
35. Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 2013; 8:165-169.
36. Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66:253-258.
37. Thompson KA, Churchill MJ, Gorry PR, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol 2004; 56:873-877.
38. Cosenza MA, Zhao ML, Si Q, et al. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 2002; 12:442-455.
39. Watkins BA, Dorn HH, Kelly WB, et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science 1990; 249:549-553.
40. Wiley CA, Schrier RD, Nelson JA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 1986; 83:7089-7093.
41. Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003; 74:635-641.
42. Soulet D, Rivest S. Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol 2008; 8:508-518.
43. Colodner KJ, Montana RA, Anthony DC, et al. Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 2005; 64:163-169.
44. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119:7-35.
45. Gray LR, Cowley D, Crespan E, et al. Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses 2013; 29:365-370.
46. Barber SA, Gama L, Dudaronek JM, et al. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virusmacaque model. J Infect Dis 2006; 193:963-970.
47. Desplats P, Dumaop W, Smith D, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013; 80:1415-1423.
48. Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res 2003; 1:463-473.
49. Carroll-Anzinger D, Al-Harthi L. Gamma interferon primes productive human immunodeficiency virus infection in astrocytes. J Virol 2006; 80:541-544.
50. Gray LR, Turville SG, Hitchen TL, et al. HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One 2014; 9:e90620.
51. Letendre S, Ellis R, Deutsch R, et al.: Correlates of time-to-loss-of-viralresponse in CSF and plasma in the CHARTER cohort. In: 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, CA, USA; 2010.
52. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
53. Gray LR, Tachedjian G, Ellett AM, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One 2013; 8:e62196.
54. Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS Rev 2011; 13:135-148.
55. Honeycutt JB, Wahl A, Archin N, et al. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 2013; 10:121.
56. Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161-170.
57. Queen SE, Mears BM, Kelly KM, et al. Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol 2011; 85:9167-9175.
58. Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol 1998; 4:90-94.
59. Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999; 73:10480-10488.